Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.
Monika KoziełNaab Al-SaadySøren P HjortshøjAssen GoudevKurt HuberAriel CohenJames JinMichael MelinoShannon M WintersAndreas GoetteGregory Y H LipPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2020)
Edoxaban had comparable efficacy and safety to optimized anticoagulation with enox-warf. The primary efficacy and safety endpoint outcomes were broadly similar between VKA experienced or naïve patients.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- oral anticoagulants
- direct oral anticoagulants
- peritoneal dialysis
- left atrial
- catheter ablation
- randomized controlled trial
- type diabetes
- patient reported outcomes
- coronary artery disease
- weight loss
- open label
- percutaneous coronary intervention
- skeletal muscle
- mitral valve
- patient reported